Cohance Lifesciences Ltd (BOM:543064) (Q1 2027) Earnings Call Highlights: Navigating a ...

Negative Points

• Cohance Lifesciences Ltd ( BOM:543064 ) reported a 23% year-on-year decline in consolidated revenue for Q1 FY27, with pharma CDMO revenue down 38.7% due to shipment phasing.

• Adjusted EBITDA margin fell to 2.2% in Q1, reflecting lower revenue base, negative operating leverage, and the impact of subsidiary consolidation.

• NJ Bio's performance weighed significantly on consolidated profitability, reporting an adjusted EBITDA loss of $328 million and lower-than-expected revenue.

• The specialty chemicals segment declined 34.7% year-on-year in Q1, primarily due to expected H2-dominated phasing of products in AgChem CDMO.

• The formulation business performed below expectations, impacted by an API production delay, lower demand for a mature product, and a customer-led change in pack configuration.

• The company received a Form 483 with five observations from the USFDA following an inspection of its Pasha Milan facility, though none related to data integrity.

• Cohance Lifesciences Ltd ( BOM:543064 ) faces ongoing challenges at its Nacharam facility, with remediation and operational stabilization remaining an immediate priority.

• The company's $1 billion sales target for FY30 remains uncertain, with management indicating it may be an aspiration rather than a firm commitment.

• Biotech funding environment continues to influence timing of customer decisions, particularly for NJ Bio's FTE program renewals.

• The company expects margin recovery to be weighted towards the second half of the year, with near-term profitability remaining under pressure.

Q & A Highlights

Q: What is the growth outlook for each business segment over the next 2-3 years, and how should we think about revenue growth for FY27 and beyond? A: Himanshu Agarwal (CFO) provided a detailed outlook: The nucleic acid business (Seppala) has a solid chance of almost doubling in 3-4 years. The ADC business is currently cost-heavy, but the goal is to align costs with revenue generation. The small molecule CDMO business is seeing solid reload orders and conversions, with a strong second half expected. The API Plus business is the bedrock of the company, offering steady, sustainable growth with a potential to reach only 30-40% of its full potential over 3-5 years. Specialty chemicals have strong potential to improve profitability and topline by partnering with innovators. Overall, solid growth should become visible in the second half of FY27.

Q: How is the macro environment for the Indian CDMO industry, especially regarding geopolitical trends and the Department of Defense list, translating into RFQs and order win rates? A: Yann D'Herve (CEO, Pharma CDMO) stated that the megatrend for Indian CDMOs remains positive. Large pharma and biotech companies are diversifying their supply chains and increasingly sourcing R&D and manufacturing support from India. This is translating into an increased number of RFQs, especially for late-stage (Phase 3 and commercial) programs. However, conversion takes longer as clients typically already have one or two existing sources and are not in a hurry to change.

Q: What makes a customer choose Cohance over other CDMO companies in the highly competitive small molecule space? A: Umang Vohra (Chairman & Group CEO) explained that the competitive advantage comes from three key areas: 1) Deep, long-term anchor relationships built on trust, which take 7-10 years to develop and are not easily replaceable. 2) A strong scientific envelope and differentiated capabilities that make Cohance a go-to partner for solving complex problems. 3) Cost competitiveness, though this is not a sustainable long-term proposition. The focus is on leveraging existing relationships and scientific prowess to win new business.

Q: With 10 Phase 3 assets in the pipeline, do you have confidence in delivering high growth over the next 2-3 years? A: Yann D'Herve (CEO, Pharma CDMO) expressed confidence, noting that the commercial portfolio has a "binodal distribution" with many newly approved molecules in a growth phase, which is driving reload orders. For the Phase 3 pipeline, they expect more than 50% of the molecules to receive approval, which will feed the maturing pipeline and support growth in the small molecule CDMO business.

Q: Are there any products in the existing commercial portfolio likely to see patent expiration in the near future? A: Yann D'Herve (CEO, Pharma CDMO) confirmed that two molecules are expected to have patent expiration. However, since Cohance supplies intermediates for these products, the impact has already been seen in the past two fiscal years, and the decrease is already reflected in the current revenue base.

Q: Do you still retain the $1 billion sales target for FY30? A: Umang Vohra (Chairman & Group CEO) stated that he does not yet have the granularity to confirm the target. He views it as an aspiration and will provide a firmer answer by December. He acknowledged that the company may be a bit away from that target over the next 3-4 years but believes it is a great aspiration for the business.

Q: Can you provide color on the restocking of molecules, specifically how much of the ?260 crore destocking impact will be recovered this year? A: Himanshu Agarwal (CFO) said that of the two molecules, one has been announced as coming back, with the order spread over two years. It is too early to quantify how much of the ?260 crore will come in this year, and clarity will be provided by the end of the second quarter call.

Q: How should we look at the segmental mix, given that API Plus has grown to 60% of revenue, and what is the profitability profile of this business? A: Gunjan Singh (CEO, API Plus) highlighted that the API Plus portfolio is highly differentiated, concentrated on CNS and controlled substances, which have high entry barriers. The business has strong relationships with innovators, commanding over 50% global market share in some products. The margin profile is among the top tier in the generic API space. The segment is expected to see sustained growth backed by new product additions, with 7 new API filings targeted for FY27.

Q: What is the first milestone for EBITDA margin over the next 2-3 years? A: Himanshu Agarwal (CFO) indicated that for the current year, the margin should be closer to the previous year's percentage, with acceleration expected from FY28 onwards as operating leverage plays in with top-line growth.

Q: Can you provide a breakdown of other expenses, and will they remain elevated? A: Himanshu Agarwal (CFO) clarified that there are no merger-related one-off expenses in the quarter. The other expenses are regular administrative costs, and they should be assumed to continue at similar levels for the year.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .